PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32259714-2 2020 The gut-liver axis is the main site for the regulation of BA synthesis and BA pool size via the combined action of the nuclear Farnesoid X Receptor (FXR) and the enterokine Fibroblast Growth Factor 19 (FGF19). Bile Acids and Salts 58-60 fibroblast growth factor 15 Mus musculus 173-200 32259714-2 2020 The gut-liver axis is the main site for the regulation of BA synthesis and BA pool size via the combined action of the nuclear Farnesoid X Receptor (FXR) and the enterokine Fibroblast Growth Factor 19 (FGF19). Bile Acids and Salts 58-60 fibroblast growth factor 15 Mus musculus 202-207 32259714-2 2020 The gut-liver axis is the main site for the regulation of BA synthesis and BA pool size via the combined action of the nuclear Farnesoid X Receptor (FXR) and the enterokine Fibroblast Growth Factor 19 (FGF19). Bile Acids and Salts 75-77 fibroblast growth factor 15 Mus musculus 202-207 32259714-7 2020 FINDINGS: FGF19-M52 reduced BA synthesis and pool size, modulated its composition and protected mice from intestinal inflammation. Bile Acids and Salts 28-30 fibroblast growth factor 15 Mus musculus 10-15 32259714-11 2020 INTERPRETATION: Reactivation of the FXR-FGF19 axis in a murine model of intestinal inflammation could bona fide provide positive changes in BA metabolism with consequent reduction of intestinal inflammation and modulation of microbiota. Bile Acids and Salts 140-142 fibroblast growth factor 15 Mus musculus 40-45 32259714-12 2020 These results point to the therapeutic potential of FGF19 in the treatment of intestinal inflammation with concomitant derangement of BA homeostasis. Bile Acids and Salts 134-136 fibroblast growth factor 15 Mus musculus 52-57 32116693-9 2020 TPE-CA maintained the homeostasis of bile acids via modulation of the liver-gut axis related farnesoid X receptor (FXR)/fibroblast growth factor 15 (FGF15) pathway and FXR-targeted protein. Bile Acids and Salts 37-47 fibroblast growth factor 15 Mus musculus 120-147 32116693-9 2020 TPE-CA maintained the homeostasis of bile acids via modulation of the liver-gut axis related farnesoid X receptor (FXR)/fibroblast growth factor 15 (FGF15) pathway and FXR-targeted protein. Bile Acids and Salts 37-47 fibroblast growth factor 15 Mus musculus 149-154 31206730-1 2020 Farnesoid X receptor (FXR) induces fibroblast growth factor 15 (FGF15; human ortholog FGF19) in the gut to potently inhibit bile acid (BA) synthesis in the liver. Bile Acids and Salts 124-133 fibroblast growth factor 15 Mus musculus 64-69 31206730-1 2020 Farnesoid X receptor (FXR) induces fibroblast growth factor 15 (FGF15; human ortholog FGF19) in the gut to potently inhibit bile acid (BA) synthesis in the liver. Bile Acids and Salts 135-137 fibroblast growth factor 15 Mus musculus 64-69 31767164-1 2019 OBJECTIVE: Fibroblast growth factor 19 (FGF19) is a postprandial hormone which plays diverse roles in the regulation of bile acid, glucose, and lipid metabolism. Bile Acids and Salts 120-129 fibroblast growth factor 15 Mus musculus 11-38 31645370-10 2020 It was suggested that the cytokine/c-Jun N-terminal kinase signaling pathway and the pregnane X receptor-mediated pathway are the predominant mechanisms, preferred over the FXR/small heterodimer partner and FXR/fibroblast growth factor 15 pathways, for controlling BA synthesis under hydrophobic BA composition. Bile Acids and Salts 265-267 fibroblast growth factor 15 Mus musculus 211-238 31920680-1 2019 Endocrine fibroblast growth factor (FGF) 19 has been shown to be capable of maintaining bile acid (BA) homeostasis and thus hold promise to be a potential therapeutic agent for cholestasis liver disease. Bile Acids and Salts 99-101 fibroblast growth factor 15 Mus musculus 10-43 31767164-1 2019 OBJECTIVE: Fibroblast growth factor 19 (FGF19) is a postprandial hormone which plays diverse roles in the regulation of bile acid, glucose, and lipid metabolism. Bile Acids and Salts 120-129 fibroblast growth factor 15 Mus musculus 40-45 31767164-3 2019 The primary target organ of FGF19 is the liver, where it regulates bile acid homeostasis in response to nutrient absorption. Bile Acids and Salts 67-76 fibroblast growth factor 15 Mus musculus 28-33 31767164-10 2019 In mice treated with FGF19, there was a significant reduction in the mRNA expression of genes associated with hepatic bile acid synthesis enzymes, lowered levels of hepatic bile acid species, and a significant increase in fecal energy content, all indicative of reduced lipid absorption in animals treated with FGF19. Bile Acids and Salts 118-127 fibroblast growth factor 15 Mus musculus 21-26 31767164-10 2019 In mice treated with FGF19, there was a significant reduction in the mRNA expression of genes associated with hepatic bile acid synthesis enzymes, lowered levels of hepatic bile acid species, and a significant increase in fecal energy content, all indicative of reduced lipid absorption in animals treated with FGF19. Bile Acids and Salts 173-182 fibroblast growth factor 15 Mus musculus 21-26 31767164-12 2019 Our data suggest that the primary way in which exogenous FGF19 lowers body weight in mice may be through the inhibition of bile acid synthesis and subsequently a reduction of dietary lipid absorption. Bile Acids and Salts 123-132 fibroblast growth factor 15 Mus musculus 57-62 31201556-2 2019 FXR and its hepatic and intestinal target genes, small heterodimer partner (SHP, NR0B2) and fibroblast growth factor 15/19 (Fgf15 in mice, FGF19 in humans), transcriptionally regulate BA synthesis, detoxification, secretion, and absorption in the enterohepatic circulation. Bile Acids and Salts 184-186 fibroblast growth factor 15 Mus musculus 92-119 30679232-1 2019 Fibroblast growth factor (FGF)19, an endocrine hormone produced in the gut, acts in the liver to control bile acid synthesis. Bile Acids and Salts 105-114 fibroblast growth factor 15 Mus musculus 0-32 30387017-6 2019 Using dual 1H/19F MRI of the gallbladders of live mice fed 19F-labeled bile acid analogues, we were able to differentiate wild-type mice from strains deficient in intestinal expression of a key bile acid transporter, the apical sodium-dependent bile acid transporter (ASBT), or FGF15, the mouse homologue of FGF19. Bile Acids and Salts 71-80 fibroblast growth factor 15 Mus musculus 278-283 30387017-6 2019 Using dual 1H/19F MRI of the gallbladders of live mice fed 19F-labeled bile acid analogues, we were able to differentiate wild-type mice from strains deficient in intestinal expression of a key bile acid transporter, the apical sodium-dependent bile acid transporter (ASBT), or FGF15, the mouse homologue of FGF19. Bile Acids and Salts 71-80 fibroblast growth factor 15 Mus musculus 308-313 31254596-12 2019 In accordance with its murine homolog FGF15, FGF19 might trigger relaxation and filling of the gallbladder which, in combination with increased cholesterol saturation and BA hydrophobicity, would enhance the risk of gallstone development. Bile Acids and Salts 171-173 fibroblast growth factor 15 Mus musculus 45-50 32694803-1 2019 Fibroblast growth factor (FGF) 15 in mice and its human orthologue FGF19 (together denoted FGF15/19) are gut hormones that control homeostasis of bile acids and glucose during the transition from the fed to the fasted state. Bile Acids and Salts 146-156 fibroblast growth factor 15 Mus musculus 0-33 30996006-1 2019 The bile acid (BA) nuclear receptor, farnesoid X receptor (FXR/NR1H4), maintains metabolic homeostasis by transcriptional control of numerous genes, including an intestinal hormone, fibroblast growth factor-19 (FGF19; FGF15 in mice). Bile Acids and Salts 4-13 fibroblast growth factor 15 Mus musculus 182-209 30996006-1 2019 The bile acid (BA) nuclear receptor, farnesoid X receptor (FXR/NR1H4), maintains metabolic homeostasis by transcriptional control of numerous genes, including an intestinal hormone, fibroblast growth factor-19 (FGF19; FGF15 in mice). Bile Acids and Salts 4-13 fibroblast growth factor 15 Mus musculus 211-216 30996006-1 2019 The bile acid (BA) nuclear receptor, farnesoid X receptor (FXR/NR1H4), maintains metabolic homeostasis by transcriptional control of numerous genes, including an intestinal hormone, fibroblast growth factor-19 (FGF19; FGF15 in mice). Bile Acids and Salts 4-13 fibroblast growth factor 15 Mus musculus 218-223 30996006-1 2019 The bile acid (BA) nuclear receptor, farnesoid X receptor (FXR/NR1H4), maintains metabolic homeostasis by transcriptional control of numerous genes, including an intestinal hormone, fibroblast growth factor-19 (FGF19; FGF15 in mice). Bile Acids and Salts 15-17 fibroblast growth factor 15 Mus musculus 182-209 30996006-1 2019 The bile acid (BA) nuclear receptor, farnesoid X receptor (FXR/NR1H4), maintains metabolic homeostasis by transcriptional control of numerous genes, including an intestinal hormone, fibroblast growth factor-19 (FGF19; FGF15 in mice). Bile Acids and Salts 15-17 fibroblast growth factor 15 Mus musculus 211-216 30996006-1 2019 The bile acid (BA) nuclear receptor, farnesoid X receptor (FXR/NR1H4), maintains metabolic homeostasis by transcriptional control of numerous genes, including an intestinal hormone, fibroblast growth factor-19 (FGF19; FGF15 in mice). Bile Acids and Salts 15-17 fibroblast growth factor 15 Mus musculus 218-223 30996006-3 2019 Recently, phosphorylation at Tyr-67 by the FGF15/19 signaling-activated nonreceptor tyrosine kinase Src was shown to be important for FXR function in BA homeostasis. Bile Acids and Salts 150-152 fibroblast growth factor 15 Mus musculus 43-51 31201556-2 2019 FXR and its hepatic and intestinal target genes, small heterodimer partner (SHP, NR0B2) and fibroblast growth factor 15/19 (Fgf15 in mice, FGF19 in humans), transcriptionally regulate BA synthesis, detoxification, secretion, and absorption in the enterohepatic circulation. Bile Acids and Salts 184-186 fibroblast growth factor 15 Mus musculus 124-129 31201556-2 2019 FXR and its hepatic and intestinal target genes, small heterodimer partner (SHP, NR0B2) and fibroblast growth factor 15/19 (Fgf15 in mice, FGF19 in humans), transcriptionally regulate BA synthesis, detoxification, secretion, and absorption in the enterohepatic circulation. Bile Acids and Salts 184-186 fibroblast growth factor 15 Mus musculus 139-144 30124818-3 2018 At adulthood, FGF15/19 is mainly produced by the ileum, acting on the liver to repress hepatic bile acid synthesis and promote postprandial nutrient partitioning. Bile Acids and Salts 95-104 fibroblast growth factor 15 Mus musculus 14-22 30247920-0 2018 Attenuated Accumulation of Novel Fluorine (19F)-Labeled Bile Acid Analogues in Gallbladders of Fibroblast Growth Factor-15 (FGF15)-Deficient Mice. Bile Acids and Salts 56-65 fibroblast growth factor 15 Mus musculus 95-122 30464200-0 2018 Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis. Bile Acids and Salts 23-32 fibroblast growth factor 15 Mus musculus 64-69 30464200-1 2018 Critical regulation of bile acid (BA) pool size and composition occurs via an intensive molecular crosstalk between the liver and gut, orchestrated by the combined actions of the nuclear Farnesoid X receptor (FXR) and the enterokine fibroblast growth factor 19 (FGF19) with the final aim of reducing hepatic BA synthesis in a negative feedback fashion. Bile Acids and Salts 23-32 fibroblast growth factor 15 Mus musculus 233-260 30464200-1 2018 Critical regulation of bile acid (BA) pool size and composition occurs via an intensive molecular crosstalk between the liver and gut, orchestrated by the combined actions of the nuclear Farnesoid X receptor (FXR) and the enterokine fibroblast growth factor 19 (FGF19) with the final aim of reducing hepatic BA synthesis in a negative feedback fashion. Bile Acids and Salts 23-32 fibroblast growth factor 15 Mus musculus 262-267 30464200-1 2018 Critical regulation of bile acid (BA) pool size and composition occurs via an intensive molecular crosstalk between the liver and gut, orchestrated by the combined actions of the nuclear Farnesoid X receptor (FXR) and the enterokine fibroblast growth factor 19 (FGF19) with the final aim of reducing hepatic BA synthesis in a negative feedback fashion. Bile Acids and Salts 34-36 fibroblast growth factor 15 Mus musculus 233-260 30464200-1 2018 Critical regulation of bile acid (BA) pool size and composition occurs via an intensive molecular crosstalk between the liver and gut, orchestrated by the combined actions of the nuclear Farnesoid X receptor (FXR) and the enterokine fibroblast growth factor 19 (FGF19) with the final aim of reducing hepatic BA synthesis in a negative feedback fashion. Bile Acids and Salts 34-36 fibroblast growth factor 15 Mus musculus 262-267 30464200-1 2018 Critical regulation of bile acid (BA) pool size and composition occurs via an intensive molecular crosstalk between the liver and gut, orchestrated by the combined actions of the nuclear Farnesoid X receptor (FXR) and the enterokine fibroblast growth factor 19 (FGF19) with the final aim of reducing hepatic BA synthesis in a negative feedback fashion. Bile Acids and Salts 308-310 fibroblast growth factor 15 Mus musculus 233-260 30464200-1 2018 Critical regulation of bile acid (BA) pool size and composition occurs via an intensive molecular crosstalk between the liver and gut, orchestrated by the combined actions of the nuclear Farnesoid X receptor (FXR) and the enterokine fibroblast growth factor 19 (FGF19) with the final aim of reducing hepatic BA synthesis in a negative feedback fashion. Bile Acids and Salts 308-310 fibroblast growth factor 15 Mus musculus 262-267 30464200-6 2018 Expression of the BA synthesis rate-limiting enzyme Cyp7a1 is reduced in FGF19-M52-treated mice compared to the GFP-treated control group with consequent reduction of BA pool and hepatic concentration. Bile Acids and Salts 18-20 fibroblast growth factor 15 Mus musculus 73-78 30464200-6 2018 Expression of the BA synthesis rate-limiting enzyme Cyp7a1 is reduced in FGF19-M52-treated mice compared to the GFP-treated control group with consequent reduction of BA pool and hepatic concentration. Bile Acids and Salts 167-169 fibroblast growth factor 15 Mus musculus 73-78 30464200-8 2018 Our data bona fide suggest the therapeutic potential of targeting the FXR-FGF19 axis to reduce hepatic BA synthesis in the control of BA-associated risk of fibrosis and hepatocarcinoma development. Bile Acids and Salts 103-105 fibroblast growth factor 15 Mus musculus 74-79 30464200-8 2018 Our data bona fide suggest the therapeutic potential of targeting the FXR-FGF19 axis to reduce hepatic BA synthesis in the control of BA-associated risk of fibrosis and hepatocarcinoma development. Bile Acids and Salts 134-136 fibroblast growth factor 15 Mus musculus 74-79 30247920-0 2018 Attenuated Accumulation of Novel Fluorine (19F)-Labeled Bile Acid Analogues in Gallbladders of Fibroblast Growth Factor-15 (FGF15)-Deficient Mice. Bile Acids and Salts 56-65 fibroblast growth factor 15 Mus musculus 124-129 30247920-2 2018 In the current study, we explored the ability of this approach to differentiate fibroblast growth factor-15 (FGF15)-deficient from wild-type (WT) mice, a potential diagnostic test for bile acid diarrhea, a commonly misdiagnosed disorder. Bile Acids and Salts 184-193 fibroblast growth factor 15 Mus musculus 80-107 30247920-2 2018 In the current study, we explored the ability of this approach to differentiate fibroblast growth factor-15 (FGF15)-deficient from wild-type (WT) mice, a potential diagnostic test for bile acid diarrhea, a commonly misdiagnosed disorder. Bile Acids and Salts 184-193 fibroblast growth factor 15 Mus musculus 109-114 30247920-6 2018 Both 19F bile acid analogues concentrated in the gallbladders of FGF15-deficient and WT mice, attaining peak concentrations at approximately 8.5 h after oral dosing. Bile Acids and Salts 9-18 fibroblast growth factor 15 Mus musculus 65-70 30247920-9 2018 Our finding that 19F MRI differentiates FGF15-deficient from WT mice provides additional proof-of-concept for the development of 19F bile acid analogues and 19F MRI as a clinical test to diagnose bile acid diarrhea due to FGF19 deficiency and other disorders. Bile Acids and Salts 133-142 fibroblast growth factor 15 Mus musculus 40-45 30247920-9 2018 Our finding that 19F MRI differentiates FGF15-deficient from WT mice provides additional proof-of-concept for the development of 19F bile acid analogues and 19F MRI as a clinical test to diagnose bile acid diarrhea due to FGF19 deficiency and other disorders. Bile Acids and Salts 196-205 fibroblast growth factor 15 Mus musculus 40-45 29876009-1 2018 Fibroblast growth factor-19 (human FGF19; murine FGF15) suppresses bile acid synthesis. Bile Acids and Salts 67-76 fibroblast growth factor 15 Mus musculus 49-54 29159825-6 2018 Mediated by a lower farnesoid X receptor (FXR) activity in enterocytes, lower fibroblast growth factor (FGF)-15 protein secretion was associated with increased hepatic cytochrome P450 enzyme (Cyp)-7a1 protein expression and circulating bile acid levels. Bile Acids and Salts 236-245 fibroblast growth factor 15 Mus musculus 78-111 29159825-13 2018 Targeted interventions improve bile acid-FXR-FGF15 signaling by modulation of hepatic Cyp7a1 and lipid metabolism, and reduce ethanol-induced liver disease in mice. Bile Acids and Salts 31-40 fibroblast growth factor 15 Mus musculus 45-50 29672888-3 2018 The mechanisms by which Fgf15 promotes liver regeneration are unclear, but Fgf15 may do so indirectly by reducing BA levels and/or directly by promoting cell proliferation. Bile Acids and Salts 114-116 fibroblast growth factor 15 Mus musculus 75-80 29672888-5 2018 In this study, we aimed to clarify these relationships by generating Fgf15 Tet-Off, transgenic mice (Fgf15 Tg) that had very low BA levels as a result from overexpressed Fgf15-mediated suppression of BA synthesis. Bile Acids and Salts 129-131 fibroblast growth factor 15 Mus musculus 101-106 29876009-10 2018 These findings confirm FGF15, the murine homolog of FGF19, plays a key role in modulating gallbladder filling and bile acid homeostasis. Bile Acids and Salts 114-123 fibroblast growth factor 15 Mus musculus 23-28 29876009-10 2018 These findings confirm FGF15, the murine homolog of FGF19, plays a key role in modulating gallbladder filling and bile acid homeostasis. Bile Acids and Salts 114-123 fibroblast growth factor 15 Mus musculus 52-57 29295820-1 2018 Diet1 modulates intestinal production of the hormone, fibroblast growth factor (FGF)15, which signals in liver to regulate bile acid synthesis. Bile Acids and Salts 123-132 fibroblast growth factor 15 Mus musculus 80-86 29404440-0 2017 Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Bile Acids and Salts 28-37 fibroblast growth factor 15 Mus musculus 11-16 29290621-16 2018 From the intestine, bile acids stimulate FGF15 secretion, leading to activation of the FGF receptors in hypothalamic AGRP/NPY neurons. Bile Acids and Salts 20-30 fibroblast growth factor 15 Mus musculus 41-46 28498614-9 2017 Fgf15/FGF19 expression was induced in polarized human enterocyte-models and mouse organoids by basolateral incubation with a high concentration (1 mM) of conjugated bile acids. Bile Acids and Salts 165-175 fibroblast growth factor 15 Mus musculus 0-5 28498614-11 2017 Enterocytes sense highly elevated levels of (conjugated) bile acids in the systemic circulation to induce FGF15/19, which modulates hepatic bile acid synthesis and uptake. Bile Acids and Salts 57-67 fibroblast growth factor 15 Mus musculus 106-114 28498614-11 2017 Enterocytes sense highly elevated levels of (conjugated) bile acids in the systemic circulation to induce FGF15/19, which modulates hepatic bile acid synthesis and uptake. Bile Acids and Salts 57-66 fibroblast growth factor 15 Mus musculus 106-114 29290621-3 2018 As bile acids stimulate the release of FGF19/FGF15 into the circulation, we pursued the potential of bile acids to improve glucose tolerance via a gut-brain axis involving FXR and FGF15/FGF19 within enterocytes and FGF receptors on hypothalamic AGRP/NPY neurons. Bile Acids and Salts 3-13 fibroblast growth factor 15 Mus musculus 39-44 29290621-3 2018 As bile acids stimulate the release of FGF19/FGF15 into the circulation, we pursued the potential of bile acids to improve glucose tolerance via a gut-brain axis involving FXR and FGF15/FGF19 within enterocytes and FGF receptors on hypothalamic AGRP/NPY neurons. Bile Acids and Salts 3-13 fibroblast growth factor 15 Mus musculus 45-50 28888832-10 2017 By the suppression of intestinal FXR/FGF-15 signaling, hepatic bile-acid synthesis gene expression was increased leading to an elevation of secondary and hydrophobic bile acids in liver, bile, and intestine. Bile Acids and Salts 63-72 fibroblast growth factor 15 Mus musculus 37-43 28888832-10 2017 By the suppression of intestinal FXR/FGF-15 signaling, hepatic bile-acid synthesis gene expression was increased leading to an elevation of secondary and hydrophobic bile acids in liver, bile, and intestine. Bile Acids and Salts 166-176 fibroblast growth factor 15 Mus musculus 37-43 28981086-3 2017 Fibroblast growth factor 19 (FGF19, rodent FGF15) is an enterokine that regulates liver bile acid and lipid metabolism, and stimulates hepatocellular protein synthesis and proliferation. Bile Acids and Salts 88-97 fibroblast growth factor 15 Mus musculus 0-27 28981086-3 2017 Fibroblast growth factor 19 (FGF19, rodent FGF15) is an enterokine that regulates liver bile acid and lipid metabolism, and stimulates hepatocellular protein synthesis and proliferation. Bile Acids and Salts 88-97 fibroblast growth factor 15 Mus musculus 29-34 28981086-3 2017 Fibroblast growth factor 19 (FGF19, rodent FGF15) is an enterokine that regulates liver bile acid and lipid metabolism, and stimulates hepatocellular protein synthesis and proliferation. Bile Acids and Salts 88-97 fibroblast growth factor 15 Mus musculus 43-48 28119353-1 2017 OBJECTIVE: Fibroblast growth factor 15/19 (FGF15/19), an enterokine that regulates synthesis of hepatic bile acids (BA), has been proposed to influence fat metabolism. Bile Acids and Salts 104-114 fibroblast growth factor 15 Mus musculus 43-51 28673684-2 2017 Fibroblast growth factor 15 (FGF15), an endocrine factor mainly produced in the distal part of small intestine, has emerged to be a critical factor in regulating bile acid homeostasis, energy metabolism, and liver regeneration. Bile Acids and Salts 162-171 fibroblast growth factor 15 Mus musculus 0-27 28673684-2 2017 Fibroblast growth factor 15 (FGF15), an endocrine factor mainly produced in the distal part of small intestine, has emerged to be a critical factor in regulating bile acid homeostasis, energy metabolism, and liver regeneration. Bile Acids and Salts 162-171 fibroblast growth factor 15 Mus musculus 29-34 28673684-7 2017 Furthermore, FGF15 deficiency resulted in abnormal bile acid homeostasis, increased insulin resistance, increased HFD-induced serum triglycerides, decreased inductions of hepatic cholesterol content by HFD, and altered gene expression of lipid metabolic enzymes. Bile Acids and Salts 51-60 fibroblast growth factor 15 Mus musculus 13-18 28673684-8 2017 These data suggest that FGF15 improves lipid homeostasis and reduces bile acid synthesis, but promotes fibrosis during the development of NASH. Bile Acids and Salts 69-78 fibroblast growth factor 15 Mus musculus 24-29 28189755-9 2017 RESULTS: Both FGF15 and FGF19 hormones repressed bile acid synthesis (p<0.001 for both). Bile Acids and Salts 49-58 fibroblast growth factor 15 Mus musculus 14-19 28487440-1 2017 Bile acid (BA) production in mice is regulated by hepatic farnesoid X receptors and by intestinal fibroblast growth factor (FGF)-15 (in humans, FGF-19), a suppressor of BA synthesis that also reduces serum triglycerides and glucose. Bile Acids and Salts 0-9 fibroblast growth factor 15 Mus musculus 98-131 28487440-1 2017 Bile acid (BA) production in mice is regulated by hepatic farnesoid X receptors and by intestinal fibroblast growth factor (FGF)-15 (in humans, FGF-19), a suppressor of BA synthesis that also reduces serum triglycerides and glucose. Bile Acids and Salts 11-13 fibroblast growth factor 15 Mus musculus 98-131 28487440-1 2017 Bile acid (BA) production in mice is regulated by hepatic farnesoid X receptors and by intestinal fibroblast growth factor (FGF)-15 (in humans, FGF-19), a suppressor of BA synthesis that also reduces serum triglycerides and glucose. Bile Acids and Salts 169-171 fibroblast growth factor 15 Mus musculus 98-131 28969019-0 2017 Repression of intestinal transporters and FXR-FGF15 signaling explains bile acids dysregulation in experimental colitis-associated colon cancer. Bile Acids and Salts 71-81 fibroblast growth factor 15 Mus musculus 46-51 28969019-5 2017 CAC mice were characterized by an accumulation of BAs in various compartments except ileum, which is in line with repressed ileal FXR-FGF15 feedback signaling and the increased expression of hepatic CYP7A1. Bile Acids and Salts 50-53 fibroblast growth factor 15 Mus musculus 134-139 28872123-3 2017 After ileal resection, circulating blood is permanently devoid of the ileum-specific endocrine hormone fibroblast growth factor 15 (FGF15), which releases its endocrinal inhibition of bile acid synthesis in the liver. Bile Acids and Salts 184-193 fibroblast growth factor 15 Mus musculus 103-130 28872123-3 2017 After ileal resection, circulating blood is permanently devoid of the ileum-specific endocrine hormone fibroblast growth factor 15 (FGF15), which releases its endocrinal inhibition of bile acid synthesis in the liver. Bile Acids and Salts 184-193 fibroblast growth factor 15 Mus musculus 132-137 28189755-9 2017 RESULTS: Both FGF15 and FGF19 hormones repressed bile acid synthesis (p<0.001 for both). Bile Acids and Salts 49-58 fibroblast growth factor 15 Mus musculus 24-29 28508871-6 2017 We show that the hepatocyte-specific deletion of Stat3, genetic ablation of Il6, treatment with a neutralizing anti-IL-6 antibody or administration of a small-molecule JAK inhibitor, abolishes FGF19-induced tumorigenesis, while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact. Bile Acids and Salts 265-274 fibroblast growth factor 15 Mus musculus 193-198 28065787-14 2017 PX20606 and FGF19 each increased the ratio of muricholate:cholate in bile, inducing a more hydrophilic bile salt pool. Bile Acids and Salts 103-112 fibroblast growth factor 15 Mus musculus 12-17 28065787-17 2017 CONCLUSIONS: Hydrophilicity of the bile salt pool, controlled by FXR and FGF15/19, is an important determinant of cholesterol removal via TICE. Bile Acids and Salts 35-44 fibroblast growth factor 15 Mus musculus 73-81 28130274-5 2017 The absence of gut microbiota changed the bile acid composition in the ileum, which was associated with activation of the enterohepatic fibroblast growth factor 15, fibroblast growth factor receptor 4 axis, and reduction of cholesterol 7alpha-hydroxylase and hepatic bile acid synthesis, resulting in the accumulation of liver cholesterol content. Bile Acids and Salts 42-51 fibroblast growth factor 15 Mus musculus 136-163 28041926-5 2017 We elucidate that the mechanism of FGF21 induced bile acid changes is mainly through antagonizing FGF15/19 function on liver betaKlotho/FGFR4 receptor complex; thus inhibiting FGF15/19-mediated suppression of Cyp7a1 expression. Bile Acids and Salts 49-58 fibroblast growth factor 15 Mus musculus 98-106 28178326-2 2017 FGF19 is secreted and signals to the liver, where it contributes to the homeostasis of bile acid (BA), lipid and carbohydrate metabolism. Bile Acids and Salts 87-96 fibroblast growth factor 15 Mus musculus 0-5 28178326-2 2017 FGF19 is secreted and signals to the liver, where it contributes to the homeostasis of bile acid (BA), lipid and carbohydrate metabolism. Bile Acids and Salts 98-100 fibroblast growth factor 15 Mus musculus 0-5 28041926-5 2017 We elucidate that the mechanism of FGF21 induced bile acid changes is mainly through antagonizing FGF15/19 function on liver betaKlotho/FGFR4 receptor complex; thus inhibiting FGF15/19-mediated suppression of Cyp7a1 expression. Bile Acids and Salts 49-58 fibroblast growth factor 15 Mus musculus 98-103 27895309-8 2016 Additionally, disturbed bile acid regulation through the FXR-FGF15-FGFR4 pathway was observed in mice with activated beta-catenin. Bile Acids and Salts 24-33 fibroblast growth factor 15 Mus musculus 61-66 26028580-13 2015 CONCLUSIONS: In mice with humanized livers, expression of an FGF19 transgene corrects bile acid signaling defects, resulting in normalization of bile acid synthesis, the bile acid pool, and liver size. Bile Acids and Salts 86-95 fibroblast growth factor 15 Mus musculus 61-66 26418580-3 2016 We hypothesized that modulating bile acid metabolism by the gut hormone fibroblast growth factor 19 (FGF19) may represent a novel approach for treating cholangiopathy and comorbidities. Bile Acids and Salts 32-41 fibroblast growth factor 15 Mus musculus 72-99 26418580-3 2016 We hypothesized that modulating bile acid metabolism by the gut hormone fibroblast growth factor 19 (FGF19) may represent a novel approach for treating cholangiopathy and comorbidities. Bile Acids and Salts 32-41 fibroblast growth factor 15 Mus musculus 101-106 26418580-7 2016 Mechanistically, FGF19 and M70 significantly inhibited hepatic expression of Cyp7a1 and Cyp27a1, which encode enzymes responsible for the rate-limiting steps in the classic and alternate bile acid synthetic pathways, thereby reducing the hepatic bile acid pool and blood levels of bile acids. Bile Acids and Salts 187-196 fibroblast growth factor 15 Mus musculus 17-22 26418580-7 2016 Mechanistically, FGF19 and M70 significantly inhibited hepatic expression of Cyp7a1 and Cyp27a1, which encode enzymes responsible for the rate-limiting steps in the classic and alternate bile acid synthetic pathways, thereby reducing the hepatic bile acid pool and blood levels of bile acids. Bile Acids and Salts 246-255 fibroblast growth factor 15 Mus musculus 17-22 26418580-7 2016 Mechanistically, FGF19 and M70 significantly inhibited hepatic expression of Cyp7a1 and Cyp27a1, which encode enzymes responsible for the rate-limiting steps in the classic and alternate bile acid synthetic pathways, thereby reducing the hepatic bile acid pool and blood levels of bile acids. Bile Acids and Salts 281-291 fibroblast growth factor 15 Mus musculus 17-22 26418580-10 2016 CONCLUSION: These results demonstrate the potential for treating cholangiopathy by safely harnessing FGF19 biology to suppress bile acid synthesis. Bile Acids and Salts 127-136 fibroblast growth factor 15 Mus musculus 101-106 26634251-2 2015 The unusual orphan nuclear receptor, small heterodimer partner (SHP), acts as a co-repressor for many transcriptional factors and has been implicated in diverse biological pathways including FGF19-mediated repression of bile acid synthesis. Bile Acids and Salts 220-229 fibroblast growth factor 15 Mus musculus 191-196 27573244-6 2016 The elevation in circulating levels of adiponectin and Fgf15 led to normalized hepatic and serum levels of bile acids, limited hepatic accumulation of toxic bile, attenuated inflammation, and amelioration of liver injury in the ethanol-fed mNTKO mice. Bile Acids and Salts 107-117 fibroblast growth factor 15 Mus musculus 55-60 26028580-13 2015 CONCLUSIONS: In mice with humanized livers, expression of an FGF19 transgene corrects bile acid signaling defects, resulting in normalization of bile acid synthesis, the bile acid pool, and liver size. Bile Acids and Salts 145-154 fibroblast growth factor 15 Mus musculus 61-66 26028580-13 2015 CONCLUSIONS: In mice with humanized livers, expression of an FGF19 transgene corrects bile acid signaling defects, resulting in normalization of bile acid synthesis, the bile acid pool, and liver size. Bile Acids and Salts 145-154 fibroblast growth factor 15 Mus musculus 61-66 26039452-1 2015 Fibroblast growth factor 15 (FGF15) has been proposed as a postprandial hormone that signals from intestine to liver to regulate bile acid and carbohydrate homeostasis. Bile Acids and Salts 129-138 fibroblast growth factor 15 Mus musculus 0-27 26040986-0 2015 Circadian control of bile acid synthesis by a KLF15-Fgf15 axis. Bile Acids and Salts 21-30 fibroblast growth factor 15 Mus musculus 52-57 26040986-6 2015 Ileal Fgf15 is a potent inhibitor of BA synthesis. Bile Acids and Salts 37-39 fibroblast growth factor 15 Mus musculus 6-11 26039452-1 2015 Fibroblast growth factor 15 (FGF15) has been proposed as a postprandial hormone that signals from intestine to liver to regulate bile acid and carbohydrate homeostasis. Bile Acids and Salts 129-138 fibroblast growth factor 15 Mus musculus 29-34 26039452-5 2015 Consistent with the proposed endocrine role for FGF15 in liver, mice lacking hepatocyte expression of the obligate FGF15 co-receptor, beta-Klotho, have increased bile acid synthesis and reduced glycogen storage despite having supraphysiological plasma FGF15 concentrations. Bile Acids and Salts 162-171 fibroblast growth factor 15 Mus musculus 115-120 26039452-5 2015 Consistent with the proposed endocrine role for FGF15 in liver, mice lacking hepatocyte expression of the obligate FGF15 co-receptor, beta-Klotho, have increased bile acid synthesis and reduced glycogen storage despite having supraphysiological plasma FGF15 concentrations. Bile Acids and Salts 162-171 fibroblast growth factor 15 Mus musculus 115-120 25604607-3 2015 FGF19 regulates bile acid biosynthesis in the bile duct, glucose metabolism and vitamin D and phosphate homeostasis, raises the metabolic rate, reduces body weight, and ameliorates diabetes in mice. Bile Acids and Salts 16-25 fibroblast growth factor 15 Mus musculus 0-5 25346390-1 2015 Fibroblast growth factor 15 (FGF15), FGF19 in humans, is a gut-derived hormone and a key regulator of bile acids and carbohydrate metabolism. Bile Acids and Salts 102-112 fibroblast growth factor 15 Mus musculus 29-34 26045262-0 2015 Diet1 is a regulator of fibroblast growth factor 15/19-dependent bile acid synthesis. Bile Acids and Salts 65-74 fibroblast growth factor 15 Mus musculus 24-51 25582706-1 2015 Bile acids (BAs) are known to regulate BA synthesis and transport by the farnesoid X receptor in the liver (FXR-SHP) and intestine (FXR-Fgf15). Bile Acids and Salts 0-10 fibroblast growth factor 15 Mus musculus 136-141 25582706-1 2015 Bile acids (BAs) are known to regulate BA synthesis and transport by the farnesoid X receptor in the liver (FXR-SHP) and intestine (FXR-Fgf15). Bile Acids and Salts 12-14 fibroblast growth factor 15 Mus musculus 136-141 26045273-5 2015 In contrast, blocking ileal basolateral membrane bile acid transport (Ostalpha-null mice) increases ileal FGF15 expression, reduces hepatic Cyp7a1 expression, and increases the proportion of tauro-beta-muricholic acid in the bile acid pool. Bile Acids and Salts 49-58 fibroblast growth factor 15 Mus musculus 106-111 26045262-2 2015 In response to bile acid uptake in enterocytes, farnesoid X receptor is activated and induces transcription of fibroblast growth factor (FGF)15 in mice, or FGF19 in humans. Bile Acids and Salts 15-24 fibroblast growth factor 15 Mus musculus 137-143 26045262-2 2015 In response to bile acid uptake in enterocytes, farnesoid X receptor is activated and induces transcription of fibroblast growth factor (FGF)15 in mice, or FGF19 in humans. Bile Acids and Salts 15-24 fibroblast growth factor 15 Mus musculus 156-161 26045262-3 2015 FGF15/19 is secreted into the enterohepatic circulation, and through activation of hepatic receptors, leads to repression of Cyp7a1, a rate-limiting enzyme for bile acid synthesis. Bile Acids and Salts 160-169 fibroblast growth factor 15 Mus musculus 0-8 26045262-8 2015 Diet1 appears to be a control point for the production of FGF15/19 in enterocytes, and thus a regulator of bile acid and lipid homeostasis. Bile Acids and Salts 107-116 fibroblast growth factor 15 Mus musculus 58-66 26045262-10 2015 CONCLUSIONS: Further elucidation of the Diet1-FGF15/19 interaction will provide new insights into the intricate regulatory mechanisms underlying bile acid metabolism. Bile Acids and Salts 145-154 fibroblast growth factor 15 Mus musculus 46-54 24954587-9 2015 CONCLUSION: Intestinal FXR is sufficient to restore BA homeostasis through the FGF15 axis and prevent progression of liver damage to HCC even in the absence of hepatic FXR. Bile Acids and Salts 52-54 fibroblast growth factor 15 Mus musculus 79-84 25204652-3 2014 Mechanism of action studies in FGFR4-deficient mice suggest that the effects are mediated in part by increased plasma levels of adiponectin and the endocrine FGF factors FGF21 and FGF15, the latter of which increase in response to an elevated bile acid pool. Bile Acids and Salts 243-252 fibroblast growth factor 15 Mus musculus 180-185 25214402-6 2014 Moreover, administration of a bile acid-sequestering agent suppressed ileal fibroblast growth factor 15 expression, leading to increased iASBT expression to restore bile filling in the liver and biliary tree, which ameliorates steatosis and inflammation in the liver. Bile Acids and Salts 30-39 fibroblast growth factor 15 Mus musculus 76-103 25080475-4 2014 We describe a nontumorigenic FGF19 variant, M70, which regulates bile acid metabolism and, through inhibition of bile acid synthesis and reduction of excess hepatic bile acid accumulation, protects mice from liver injury induced by either extrahepatic or intrahepatic cholestasis. Bile Acids and Salts 65-74 fibroblast growth factor 15 Mus musculus 29-34 24981838-0 2014 Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Bile Acids and Salts 116-125 fibroblast growth factor 15 Mus musculus 86-94 24981838-1 2014 Bile acid (BA) biosynthesis is tightly controlled by intrahepatic negative feedback signaling elicited by BA binding to farnesoid X receptor (FXR) and also by enterohepatic communication involving ileal BA reabsorption and FGF15/19 secretion. Bile Acids and Salts 0-9 fibroblast growth factor 15 Mus musculus 223-231 24981838-1 2014 Bile acid (BA) biosynthesis is tightly controlled by intrahepatic negative feedback signaling elicited by BA binding to farnesoid X receptor (FXR) and also by enterohepatic communication involving ileal BA reabsorption and FGF15/19 secretion. Bile Acids and Salts 11-13 fibroblast growth factor 15 Mus musculus 223-231 24033844-1 2014 AIM: Bile acid synthesis is regulated by nuclear receptors including farnesoid X receptor (FXR) and small heterodimer partner (SHP), and by fibroblast growth factor 15/19 (FGF15/19). Bile Acids and Salts 5-14 fibroblast growth factor 15 Mus musculus 172-180 25080475-4 2014 We describe a nontumorigenic FGF19 variant, M70, which regulates bile acid metabolism and, through inhibition of bile acid synthesis and reduction of excess hepatic bile acid accumulation, protects mice from liver injury induced by either extrahepatic or intrahepatic cholestasis. Bile Acids and Salts 113-122 fibroblast growth factor 15 Mus musculus 29-34 25080475-4 2014 We describe a nontumorigenic FGF19 variant, M70, which regulates bile acid metabolism and, through inhibition of bile acid synthesis and reduction of excess hepatic bile acid accumulation, protects mice from liver injury induced by either extrahepatic or intrahepatic cholestasis. Bile Acids and Salts 113-122 fibroblast growth factor 15 Mus musculus 29-34 24535283-0 2014 Regulation of bile acid homeostasis by the intestinal Diet1-FGF15/19 axis. Bile Acids and Salts 14-23 fibroblast growth factor 15 Mus musculus 60-68 24068255-10 2014 Thus, the results collectively suggest that cholangiocytes may be able to actively regulate bile acid biosynthesis in cholangiocytes and even hepatocyte by secreting FGF15/19. Bile Acids and Salts 92-101 fibroblast growth factor 15 Mus musculus 166-174 24535283-2 2014 In this review, we focus on the role of the intestinal FGF15/19 hormone in modulating bile acid levels, and additional metabolic effects on glucose metabolism, nonalcoholic liver disease (NAFLD), and liver regeneration. Bile Acids and Salts 86-95 fibroblast growth factor 15 Mus musculus 55-63 24688219-1 2014 Members of the fibroblast growth factor (FGF) 19 subfamily, including FGF23, FGF15/19, and FGF21, have a role as endocrine factors which influence the metabolism of inorganic phosphate (Pi) and vitamin D, bile acid, and energy. Bile Acids and Salts 205-214 fibroblast growth factor 15 Mus musculus 41-44 24688219-8 2014 Furthermore, diurnal variations of plasma triglyceride concentrations and hepatic mRNA expression of the bile acid synthesis enzyme Cyp7a1 as one of Fgf15 negative target genes was influenced by dietary Pi restriction. Bile Acids and Salts 105-114 fibroblast growth factor 15 Mus musculus 149-154 24688219-1 2014 Members of the fibroblast growth factor (FGF) 19 subfamily, including FGF23, FGF15/19, and FGF21, have a role as endocrine factors which influence the metabolism of inorganic phosphate (Pi) and vitamin D, bile acid, and energy. Bile Acids and Salts 205-214 fibroblast growth factor 15 Mus musculus 77-85 23747249-0 2013 Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Bile Acids and Salts 73-82 fibroblast growth factor 15 Mus musculus 23-31 24118394-4 2014 Studies on such mice have concluded BA synthesis is induced due to reduced hormonal signalling by fibroblast growth factor (FGF)15 from intestine to liver. Bile Acids and Salts 36-38 fibroblast growth factor 15 Mus musculus 124-130 24165751-2 2013 Fibroblast growth factor 15/19 (FGF15 in mice, FGF19 in humans) is a hormone that functions as a central regulator of glucose, lipid and bile acid metabolism. Bile Acids and Salts 137-146 fibroblast growth factor 15 Mus musculus 0-27 24165751-2 2013 Fibroblast growth factor 15/19 (FGF15 in mice, FGF19 in humans) is a hormone that functions as a central regulator of glucose, lipid and bile acid metabolism. Bile Acids and Salts 137-146 fibroblast growth factor 15 Mus musculus 32-37 24165751-2 2013 Fibroblast growth factor 15/19 (FGF15 in mice, FGF19 in humans) is a hormone that functions as a central regulator of glucose, lipid and bile acid metabolism. Bile Acids and Salts 137-146 fibroblast growth factor 15 Mus musculus 47-52 24309182-1 2014 Fibroblast growth factor-19 (FGF-19), a bile acid-responsive enterokine, is secreted by the ileum and regulates a variety of metabolic processes. Bile Acids and Salts 40-49 fibroblast growth factor 15 Mus musculus 0-27 24309182-1 2014 Fibroblast growth factor-19 (FGF-19), a bile acid-responsive enterokine, is secreted by the ileum and regulates a variety of metabolic processes. Bile Acids and Salts 40-49 fibroblast growth factor 15 Mus musculus 29-35 25056539-1 2014 In addition to being positively regulated by prandial activity, bile acid production is also negatively controlled by the endocrine fibroblast growth factor 19 (FGF19) or the mouse ortholog FGF15 from the ileum that represses hepatic cholesterol 7 alpha-hydroxylase (Cyp7a1) expression through activating FGF receptor four (FGFR4). Bile Acids and Salts 64-73 fibroblast growth factor 15 Mus musculus 132-159 25056539-1 2014 In addition to being positively regulated by prandial activity, bile acid production is also negatively controlled by the endocrine fibroblast growth factor 19 (FGF19) or the mouse ortholog FGF15 from the ileum that represses hepatic cholesterol 7 alpha-hydroxylase (Cyp7a1) expression through activating FGF receptor four (FGFR4). Bile Acids and Salts 64-73 fibroblast growth factor 15 Mus musculus 161-166 25056539-1 2014 In addition to being positively regulated by prandial activity, bile acid production is also negatively controlled by the endocrine fibroblast growth factor 19 (FGF19) or the mouse ortholog FGF15 from the ileum that represses hepatic cholesterol 7 alpha-hydroxylase (Cyp7a1) expression through activating FGF receptor four (FGFR4). Bile Acids and Salts 64-73 fibroblast growth factor 15 Mus musculus 190-195 25056539-3 2014 Here we report that hepatocyte FGFR substrate 2alpha (FRS2alpha), a scaffold protein essential for canonical FGFRs to activate the ERK and AKT pathways, was required for the regulation of bile acid production by the FGF15/19-FGFR4 signaling axis. Bile Acids and Salts 188-197 fibroblast growth factor 15 Mus musculus 216-224 25056539-7 2014 Together, the results demonstrate that FRS2alpha-mediated pathways are essential for the FGF15/FGF19-FGFR4 signaling axis to control bile acid homeostasis. Bile Acids and Salts 133-142 fibroblast growth factor 15 Mus musculus 89-94 25056539-7 2014 Together, the results demonstrate that FRS2alpha-mediated pathways are essential for the FGF15/FGF19-FGFR4 signaling axis to control bile acid homeostasis. Bile Acids and Salts 133-142 fibroblast growth factor 15 Mus musculus 95-100 23880190-10 2013 CONCLUSIONS: Decreases in ileal FGF15, with subsequent increases in hepatic Cyp7a1 expression and bile acid synthesis appear to be necessary for the plasma cholesterol-lowering and atheroprotective effects associated with blocking intestinal bile acid absorption. Bile Acids and Salts 242-251 fibroblast growth factor 15 Mus musculus 32-37 23801799-2 2013 In mice, fibroblast growth factor (FGF) 15 (FGF19 in humans) regulates hepatic bile acid (BA) production and can also resolve diabetes. Bile Acids and Salts 79-88 fibroblast growth factor 15 Mus musculus 9-42 23801799-2 2013 In mice, fibroblast growth factor (FGF) 15 (FGF19 in humans) regulates hepatic bile acid (BA) production and can also resolve diabetes. Bile Acids and Salts 79-88 fibroblast growth factor 15 Mus musculus 44-49 23801799-2 2013 In mice, fibroblast growth factor (FGF) 15 (FGF19 in humans) regulates hepatic bile acid (BA) production and can also resolve diabetes. Bile Acids and Salts 90-92 fibroblast growth factor 15 Mus musculus 9-42 23801799-2 2013 In mice, fibroblast growth factor (FGF) 15 (FGF19 in humans) regulates hepatic bile acid (BA) production and can also resolve diabetes. Bile Acids and Salts 90-92 fibroblast growth factor 15 Mus musculus 44-49 23292666-2 2013 Fibroblast growth factor 15 (Fgf15, human FGF19) is a BA-induced ileum-derived enterokine that governs BA metabolism. Bile Acids and Salts 54-56 fibroblast growth factor 15 Mus musculus 0-27 23292666-2 2013 Fibroblast growth factor 15 (Fgf15, human FGF19) is a BA-induced ileum-derived enterokine that governs BA metabolism. Bile Acids and Salts 54-56 fibroblast growth factor 15 Mus musculus 29-34 23292666-3 2013 We evaluated the relevance of Fgf15 in the preservation of BA homeostasis after PH and its potential role in the regenerative process. Bile Acids and Salts 59-61 fibroblast growth factor 15 Mus musculus 30-35 23292666-8 2013 RESULTS: Fgf15 (-/-) mice showed marked liver injury and mortality after PH accompanied by persistently elevated intrahepatic BA levels. Bile Acids and Salts 126-128 fibroblast growth factor 15 Mus musculus 9-14 23292666-9 2013 Cholestyramine feeding and adenovirally delivered Fgf15 reduced BA levels and significantly prevented this lethal outcome. Bile Acids and Salts 64-66 fibroblast growth factor 15 Mus musculus 50-55 23292666-14 2013 CONCLUSIONS: Fgf15 is necessary to maintain BA homeostasis and prevent liver injury during liver regeneration. Bile Acids and Salts 44-46 fibroblast growth factor 15 Mus musculus 13-18 23292666-15 2013 Moreover, Fgf15 is an essential mediator of the liver growth-promoting effects of BA. Bile Acids and Salts 82-84 fibroblast growth factor 15 Mus musculus 10-15 22130247-1 2011 Human fibroblast growth factor 19 (FGF19) is an enterohepatic hormone that is involved in the regulation of hepatic metabolism of bile acids, lipids, and glucose. Bile Acids and Salts 130-140 fibroblast growth factor 15 Mus musculus 6-33 23106963-2 2012 Ileal FGF19 regulates bile acid metabolism through specifically FGFR4-KLB in hepatocytes where FGFR1 is not significant. Bile Acids and Salts 22-31 fibroblast growth factor 15 Mus musculus 6-11 22661717-6 2012 FGF19, a gut hormone whose expression and secretion is induced by intestinal bile acids, also increased hepatic FGF21 secretion. Bile Acids and Salts 77-87 fibroblast growth factor 15 Mus musculus 0-5 22661717-9 2012 We propose that the enhanced enterohepatic flux of bile acids during HF-LC consumption leads to activation of hepatic FXR and FGF19 signaling activity and an increase in FGF21 gene expression and secretion. Bile Acids and Salts 51-61 fibroblast growth factor 15 Mus musculus 126-131 21436455-1 2011 Fibroblast growth factor (FGF) 19 is an enterokine synthesized and released when bile acids are taken up into the ileum. Bile Acids and Salts 81-91 fibroblast growth factor 15 Mus musculus 0-33 21437243-0 2011 FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. Bile Acids and Salts 48-57 fibroblast growth factor 15 Mus musculus 0-5 23338060-0 2013 Liver: Fgf15 maintains bile acid homeostasis and is a key mediator of liver regeneration in mice. Bile Acids and Salts 23-32 fibroblast growth factor 15 Mus musculus 7-12 22617565-5 2012 Its cognate receptor in the liver (FGFR4) mediated the effects of FGF19 on proliferation and bile salt synthesis, while this receptor was dispensable for its effects on glucose homeostasis. Bile Acids and Salts 93-102 fibroblast growth factor 15 Mus musculus 66-71 22396169-6 2012 Mouse Fgf15 and human FGF19 play key roles in enterohepatic signaling, regulation of liver bile acid biosynthesis, gallbladder motility and metabolic homeostasis. Bile Acids and Salts 91-100 fibroblast growth factor 15 Mus musculus 6-11 21437243-1 2011 Fibroblast growth factor 19 (FGF19) is a hormone-like protein that regulates carbohydrate, lipid and bile acid metabolism. Bile Acids and Salts 101-110 fibroblast growth factor 15 Mus musculus 0-27 21437243-1 2011 Fibroblast growth factor 19 (FGF19) is a hormone-like protein that regulates carbohydrate, lipid and bile acid metabolism. Bile Acids and Salts 101-110 fibroblast growth factor 15 Mus musculus 29-34 21437243-5 2011 Our results demonstrate that FGFR4 activation mediates the induction of hepatocyte proliferation and the suppression of bile acid biosynthesis by FGF19, but is not essential for FGF19 to improve glucose and lipid metabolism in high fat diet fed mice as well as in leptin-deficient ob/ob mice. Bile Acids and Salts 120-129 fibroblast growth factor 15 Mus musculus 146-151 21691100-3 2011 We hypothesized that the altered bile acid homeostasis resulted from ileal trapping of bile acids that act via the farnesoid X receptor (FXR) to induce overexpression of FGF15. Bile Acids and Salts 33-42 fibroblast growth factor 15 Mus musculus 170-175 21691100-3 2011 We hypothesized that the altered bile acid homeostasis resulted from ileal trapping of bile acids that act via the farnesoid X receptor (FXR) to induce overexpression of FGF15. Bile Acids and Salts 87-97 fibroblast growth factor 15 Mus musculus 170-175 22130247-1 2011 Human fibroblast growth factor 19 (FGF19) is an enterohepatic hormone that is involved in the regulation of hepatic metabolism of bile acids, lipids, and glucose. Bile Acids and Salts 130-140 fibroblast growth factor 15 Mus musculus 35-40 19608735-8 2009 However, ileal mRNA expression of Fgf15 (inhibitor of bile salt synthesis) was significantly reduced, in agreement with absent inhibition of the hepatic bile salt synthesis. Bile Acids and Salts 54-63 fibroblast growth factor 15 Mus musculus 34-39 21655243-2 2011 Fgf15 is highly expressed in the ileum and functions as an endocrine signal to regulate liver function, including bile acid synthesis, hepatocyte proliferation and insulin sensitivity. Bile Acids and Salts 114-123 fibroblast growth factor 15 Mus musculus 0-5 20080590-3 2010 Analyses of functional interactions between alpha- and beta-Kl and FGF19 factors in wild-type, alpha-kl(-/-), and beta-kl(-/-) mice revealed a comprehensive regulatory scheme of mineral homeostasis involving the mutually regulated positive/negative feedback actions of alpha-Kl, FGF23, and 1,25(OH)(2)D and an analogous regulatory network composed of beta-Kl, FGF15/humanFGF19, and bile acids that regulate bile acid/cholesterol metabolism. Bile Acids and Salts 382-392 fibroblast growth factor 15 Mus musculus 67-72 20080590-3 2010 Analyses of functional interactions between alpha- and beta-Kl and FGF19 factors in wild-type, alpha-kl(-/-), and beta-kl(-/-) mice revealed a comprehensive regulatory scheme of mineral homeostasis involving the mutually regulated positive/negative feedback actions of alpha-Kl, FGF23, and 1,25(OH)(2)D and an analogous regulatory network composed of beta-Kl, FGF15/humanFGF19, and bile acids that regulate bile acid/cholesterol metabolism. Bile Acids and Salts 382-391 fibroblast growth factor 15 Mus musculus 67-72 20531290-0 2010 Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Bile Acids and Salts 83-92 fibroblast growth factor 15 Mus musculus 24-29 20531290-1 2010 Hepatic bile acid synthesis is subject to complex modes of transcriptional control, in which the bile acid-activated nuclear receptor farnesoid X receptor (FXR) in liver and intestine-derived, FXR-controlled fibroblast growth factor 15 (Fgf15) are involved. Bile Acids and Salts 8-17 fibroblast growth factor 15 Mus musculus 208-235 20531290-1 2010 Hepatic bile acid synthesis is subject to complex modes of transcriptional control, in which the bile acid-activated nuclear receptor farnesoid X receptor (FXR) in liver and intestine-derived, FXR-controlled fibroblast growth factor 15 (Fgf15) are involved. Bile Acids and Salts 8-17 fibroblast growth factor 15 Mus musculus 237-242 20531290-1 2010 Hepatic bile acid synthesis is subject to complex modes of transcriptional control, in which the bile acid-activated nuclear receptor farnesoid X receptor (FXR) in liver and intestine-derived, FXR-controlled fibroblast growth factor 15 (Fgf15) are involved. Bile Acids and Salts 97-106 fibroblast growth factor 15 Mus musculus 208-235 20531290-1 2010 Hepatic bile acid synthesis is subject to complex modes of transcriptional control, in which the bile acid-activated nuclear receptor farnesoid X receptor (FXR) in liver and intestine-derived, FXR-controlled fibroblast growth factor 15 (Fgf15) are involved. Bile Acids and Salts 97-106 fibroblast growth factor 15 Mus musculus 237-242 20531290-2 2010 The Fgf15 pathway is assumed to contribute significantly to control of hepatic bile acid synthesis. Bile Acids and Salts 79-88 fibroblast growth factor 15 Mus musculus 4-9 20531290-9 2010 In conclusion, this study is the first to demonstrate the physiological relevance of the contribution of the intestinal FXR-Fgf15 signalling pathway in control of hepatic bile acid synthesis. Bile Acids and Salts 171-180 fibroblast growth factor 15 Mus musculus 124-129 20531290-10 2010 Fgf15 contributes to the regulation of hepatic bile acid synthesis in mice mainly during the dark phase. Bile Acids and Salts 47-56 fibroblast growth factor 15 Mus musculus 0-5 20531290-11 2010 Expansion of the circulating bile acid pool as well as bile acid sequestration diminishes the contribution of intestinal FXR-Fgf15 signalling in control of hepatic bile acid synthesis and bile formation. Bile Acids and Salts 29-38 fibroblast growth factor 15 Mus musculus 125-130 34965924-1 2022 Fibroblast growth factor 15/19 (FGF15/19) are endocrine growth factors that play an important role in bile acid homeostasis. Bile Acids and Salts 102-111 fibroblast growth factor 15 Mus musculus 0-30 19706524-1 2009 FGF19 is a hormone that regulates bile acid and glucose homeostasis. Bile Acids and Salts 34-43 fibroblast growth factor 15 Mus musculus 0-5 19706524-11 2009 These results suggest that FGF19-regulated liver bile acid metabolism could be independent of its glucose-lowering effect, and direct FGFR activation in adipose tissue may play an important role in the regulation of glucose homeostasis. Bile Acids and Salts 49-58 fibroblast growth factor 15 Mus musculus 27-32 19085950-1 2009 UNLABELLED: Mouse fibroblast growth factor 15 (FGF15) and human ortholog FGF19 have been identified as the bile acid-induced intestinal factors that mediate bile acid feedback inhibition of cholesterol 7alpha-hydroxylase gene (C YP7A1) transcription in mouse liver. Bile Acids and Salts 107-116 fibroblast growth factor 15 Mus musculus 18-45 19085950-1 2009 UNLABELLED: Mouse fibroblast growth factor 15 (FGF15) and human ortholog FGF19 have been identified as the bile acid-induced intestinal factors that mediate bile acid feedback inhibition of cholesterol 7alpha-hydroxylase gene (C YP7A1) transcription in mouse liver. Bile Acids and Salts 107-116 fibroblast growth factor 15 Mus musculus 47-52 19085950-1 2009 UNLABELLED: Mouse fibroblast growth factor 15 (FGF15) and human ortholog FGF19 have been identified as the bile acid-induced intestinal factors that mediate bile acid feedback inhibition of cholesterol 7alpha-hydroxylase gene (C YP7A1) transcription in mouse liver. Bile Acids and Salts 157-166 fibroblast growth factor 15 Mus musculus 18-45 19085950-1 2009 UNLABELLED: Mouse fibroblast growth factor 15 (FGF15) and human ortholog FGF19 have been identified as the bile acid-induced intestinal factors that mediate bile acid feedback inhibition of cholesterol 7alpha-hydroxylase gene (C YP7A1) transcription in mouse liver. Bile Acids and Salts 157-166 fibroblast growth factor 15 Mus musculus 47-52 19085950-2 2009 The mechanism underlying FGF15/FGF19 inhibition of bile acid synthesis in hepatocytes remains unclear. Bile Acids and Salts 51-60 fibroblast growth factor 15 Mus musculus 25-30 18660672-7 2008 SUMMARY: Recent mouse genetic studies have broadened our understanding of molecular pathways involved in mineral and bile acid homeostasis regulated by FGF23 and FGF19, respectively. Bile Acids and Salts 117-126 fibroblast growth factor 15 Mus musculus 162-167 18660672-9 2008 Further investigations on endocrine axes mediated by the Klotho family and FGF19 subfamily members are expected to provide new insights into the molecular mechanisms by which the endocrine fibroblast growth factors regulate bile acid, energy, and phosphate/vitamin D metabolism. Bile Acids and Salts 224-233 fibroblast growth factor 15 Mus musculus 75-80 17823457-0 2007 FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. Bile Acids and Salts 36-45 fibroblast growth factor 15 Mus musculus 17-22 17823457-0 2007 FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. Bile Acids and Salts 76-85 fibroblast growth factor 15 Mus musculus 17-22 17823457-2 2007 Feedback regulation of bile acid synthesis is under the control of an endocrine pathway wherein activation of the nuclear bile acid receptor, farnesoid X receptor (FXR), induces enteric expression of the hormone, fibroblast growth factor 15 (FGF15). Bile Acids and Salts 23-32 fibroblast growth factor 15 Mus musculus 213-240 17823457-2 2007 Feedback regulation of bile acid synthesis is under the control of an endocrine pathway wherein activation of the nuclear bile acid receptor, farnesoid X receptor (FXR), induces enteric expression of the hormone, fibroblast growth factor 15 (FGF15). Bile Acids and Salts 23-32 fibroblast growth factor 15 Mus musculus 242-247 17823457-3 2007 In liver, FGF15 acts together with FXR-mediated expression of small heterodimer partner to repress bile acid synthesis. Bile Acids and Salts 99-108 fibroblast growth factor 15 Mus musculus 10-15 17823457-4 2007 Here, we show that the FXR-FGF15 pathway is disrupted in mice lacking apical ileal bile acid transporter, a model of bile acid malabsorption. Bile Acids and Salts 83-92 fibroblast growth factor 15 Mus musculus 27-32 17823457-4 2007 Here, we show that the FXR-FGF15 pathway is disrupted in mice lacking apical ileal bile acid transporter, a model of bile acid malabsorption. Bile Acids and Salts 117-126 fibroblast growth factor 15 Mus musculus 27-32 17823457-5 2007 Treatment of Asbt-/- mice with either a synthetic FXR agonist or FGF15 downregulates hepatic cholesterol 7alpha-hydroxylase mRNA levels, decreases bile acid pool size, and reduces fecal bile acid excretion. Bile Acids and Salts 147-156 fibroblast growth factor 15 Mus musculus 65-70 17823457-5 2007 Treatment of Asbt-/- mice with either a synthetic FXR agonist or FGF15 downregulates hepatic cholesterol 7alpha-hydroxylase mRNA levels, decreases bile acid pool size, and reduces fecal bile acid excretion. Bile Acids and Salts 186-195 fibroblast growth factor 15 Mus musculus 65-70 17823457-6 2007 These findings suggest that FXR agonists or FGF15 could be used therapeutically to interrupt the cycle of excessive bile acid production in patients with bile acid malabsorption. Bile Acids and Salts 116-125 fibroblast growth factor 15 Mus musculus 44-49 17823457-6 2007 These findings suggest that FXR agonists or FGF15 could be used therapeutically to interrupt the cycle of excessive bile acid production in patients with bile acid malabsorption. Bile Acids and Salts 154-163 fibroblast growth factor 15 Mus musculus 44-49 16213224-0 2005 Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Bile Acids and Salts 77-86 fibroblast growth factor 15 Mus musculus 0-27 16213224-2 2005 Here, we demonstrate that fibroblast growth factor 15 (FGF15) signals from intestine to liver to repress the gene encoding cholesterol 7alpha-hydroxylase (CYP7A1), which catalyzes the first and rate-limiting step in the classical bile acid synthetic pathway. Bile Acids and Salts 230-239 fibroblast growth factor 15 Mus musculus 26-53 16213224-2 2005 Here, we demonstrate that fibroblast growth factor 15 (FGF15) signals from intestine to liver to repress the gene encoding cholesterol 7alpha-hydroxylase (CYP7A1), which catalyzes the first and rate-limiting step in the classical bile acid synthetic pathway. Bile Acids and Salts 230-239 fibroblast growth factor 15 Mus musculus 55-60 16213224-4 2005 Mice lacking FGF15 have increased hepatic CYP7A1 mRNA and protein levels and corresponding increases in CYP7A1 enzyme activity and fecal bile acid excretion. Bile Acids and Salts 137-146 fibroblast growth factor 15 Mus musculus 13-18 33235221-2 2020 Fibroblast Growth Factor-15/19 (mouse FGF15, human FGF19) are bile acid-induced late fed-state gut hormones that decrease hepatic lipid levels by unclear mechanisms. Bile Acids and Salts 62-71 fibroblast growth factor 15 Mus musculus 0-30 33235221-2 2020 Fibroblast Growth Factor-15/19 (mouse FGF15, human FGF19) are bile acid-induced late fed-state gut hormones that decrease hepatic lipid levels by unclear mechanisms. Bile Acids and Salts 62-71 fibroblast growth factor 15 Mus musculus 38-43 34973477-0 2022 LKB1 in intestinal epithelial cells regulates bile acid metabolism by modulating FGF15/19 production. Bile Acids and Salts 46-55 fibroblast growth factor 15 Mus musculus 81-89 34973477-7 2022 A significant reduction of the farnesoid X receptor (FXR) target genes, including fibroblast growth factor 15/19 (FGF15/19), known to inhibit BA synthesis, was found in the small intestine (SI) ileum of LKB1DeltaIEC mice. Bile Acids and Salts 142-144 fibroblast growth factor 15 Mus musculus 114-122 34973477-13 2022 CONCLUSIONS: LKB1 in IECs manages BA homeostasis by controlling FGF15/19 production. Bile Acids and Salts 34-36 fibroblast growth factor 15 Mus musculus 64-72 19390091-4 2009 Here, we report surprising findings that SHP is a rapidly degraded protein via the ubiquitin-proteasomal pathway and that bile acids or bile acid-induced intestinal fibroblast growth factor 19 (FGF19) increases stability of hepatic SHP by inhibiting proteasomal degradation in an extracellular signal-regulated kinase (ERK)-dependent manner. Bile Acids and Salts 122-132 fibroblast growth factor 15 Mus musculus 165-192 19390091-4 2009 Here, we report surprising findings that SHP is a rapidly degraded protein via the ubiquitin-proteasomal pathway and that bile acids or bile acid-induced intestinal fibroblast growth factor 19 (FGF19) increases stability of hepatic SHP by inhibiting proteasomal degradation in an extracellular signal-regulated kinase (ERK)-dependent manner. Bile Acids and Salts 122-132 fibroblast growth factor 15 Mus musculus 194-199 19390091-4 2009 Here, we report surprising findings that SHP is a rapidly degraded protein via the ubiquitin-proteasomal pathway and that bile acids or bile acid-induced intestinal fibroblast growth factor 19 (FGF19) increases stability of hepatic SHP by inhibiting proteasomal degradation in an extracellular signal-regulated kinase (ERK)-dependent manner. Bile Acids and Salts 122-131 fibroblast growth factor 15 Mus musculus 194-199 18772362-3 2008 FGF-15 secretion by the intestine regulates hepatic bile acid biosynthesis. Bile Acids and Salts 52-61 fibroblast growth factor 15 Mus musculus 0-6 18179175-6 2008 FGF19 expression is regulated by the farnesoid X receptor, a nuclear hormone receptor that is a key regulator of bile acid biosynthesis and transport. Bile Acids and Salts 113-122 fibroblast growth factor 15 Mus musculus 0-5 18179175-7 2008 In line with its regulation by a bile acid receptor, FGF19 is involved in the regulation of bile acid biosynthesis and gallbladder filling. Bile Acids and Salts 33-42 fibroblast growth factor 15 Mus musculus 53-58 17627937-2 2007 FGF19 regulates bile acid homeostasis and gall bladder filling; FGF19 binds only to FGF receptor 4 (FGFR4), but its liver-specific activity cannot be explained solely by the distribution of this receptor. Bile Acids and Salts 16-25 fibroblast growth factor 15 Mus musculus 0-5 17456796-8 2007 Because FGF15 has recently been shown to function in an enterohepatic regulatory pathway to repress liver expression of bile acid homeostatic genes, its direct induction in the gut may account for indirect effects of cafestol on liver gene expression. Bile Acids and Salts 120-129 fibroblast growth factor 15 Mus musculus 8-13 16284190-7 2006 CONCLUSIONS: Hepatic PON1 and CYP7A1 mRNA expression is repressed by bile acids via FXR-mediated induction of FGF15. Bile Acids and Salts 69-79 fibroblast growth factor 15 Mus musculus 110-115 16213224-5 2005 These studies define FGF15 and FGFR4 as components of a gut-liver signaling pathway that synergizes with SHP to regulate bile acid synthesis. Bile Acids and Salts 121-130 fibroblast growth factor 15 Mus musculus 21-26 33783283-5 2021 Ileal farnesoid X receptor (FXR)-fibroblast growth factor 15 (FGF15) signaling was inhibited in response to microbial BA disturbance. Bile Acids and Salts 118-120 fibroblast growth factor 15 Mus musculus 33-60 33783283-5 2021 Ileal farnesoid X receptor (FXR)-fibroblast growth factor 15 (FGF15) signaling was inhibited in response to microbial BA disturbance. Bile Acids and Salts 118-120 fibroblast growth factor 15 Mus musculus 62-67 34965924-1 2022 Fibroblast growth factor 15/19 (FGF15/19) are endocrine growth factors that play an important role in bile acid homeostasis. Bile Acids and Salts 102-111 fibroblast growth factor 15 Mus musculus 32-40 34585527-11 2021 Increase in expression of FGF15 in intestine (P < 0.01) suggested the activation of FXR signalling pathway which might contribute to the regulation of BA synthesis enzymes, transporters, and metabolic enzymes. Bile Acids and Salts 151-153 fibroblast growth factor 15 Mus musculus 26-31 34164827-1 2021 BACKGROUND & AIM: Cholestasis is characterized by increased total bile acid (TBA) levels, which are regulated by farnesoid X receptor (FXR)/fibroblast growth factor 15 (FGF15). Bile Acids and Salts 66-75 fibroblast growth factor 15 Mus musculus 140-167 34164827-1 2021 BACKGROUND & AIM: Cholestasis is characterized by increased total bile acid (TBA) levels, which are regulated by farnesoid X receptor (FXR)/fibroblast growth factor 15 (FGF15). Bile Acids and Salts 66-75 fibroblast growth factor 15 Mus musculus 169-174 34076007-5 2021 These results suggested that VLE regulates both the NPY-mediated pathway and the bile acid-FGF15 pathway to control energy metabolism and body weight gain. Bile Acids and Salts 81-90 fibroblast growth factor 15 Mus musculus 91-96 34362888-8 2021 These data point to an important role after VSG for intestinal FGF15 to protect the organism from deleterious effects of VSG potentially by limiting the increase in circulating bile acids. Bile Acids and Salts 177-187 fibroblast growth factor 15 Mus musculus 63-68 33154041-9 2021 Circulating FGF15 activates hepatic FXR and together with hepatic Shp blocks Cyp7a1 and Cyp7b1 gene expression, key enzymes in bile acid metabolism. Bile Acids and Salts 127-136 fibroblast growth factor 15 Mus musculus 12-17 35500802-12 2022 The protein and mRNA expression of farnesoid X receptor (FXR) and fibroblast growth factor 15 (FGF15) were decreased in intestine, increased taurine-conjugated BAs inhibited the intestinal signaling pathway, which was associated with increased genes expression of enzymes in the alternative BA synthesis pathway that reduced the levels of cholesterol. Bile Acids and Salts 291-293 fibroblast growth factor 15 Mus musculus 66-93 35500802-12 2022 The protein and mRNA expression of farnesoid X receptor (FXR) and fibroblast growth factor 15 (FGF15) were decreased in intestine, increased taurine-conjugated BAs inhibited the intestinal signaling pathway, which was associated with increased genes expression of enzymes in the alternative BA synthesis pathway that reduced the levels of cholesterol. Bile Acids and Salts 291-293 fibroblast growth factor 15 Mus musculus 95-100 35105957-8 2022 Reabsorbed BA affected liver BA synthetic enzymes by regulating Fgf15 expression. Bile Acids and Salts 11-13 fibroblast growth factor 15 Mus musculus 64-69 35105957-8 2022 Reabsorbed BA affected liver BA synthetic enzymes by regulating Fgf15 expression. Bile Acids and Salts 29-31 fibroblast growth factor 15 Mus musculus 64-69 33965587-7 2021 Mechanistically, the synergistic actions of GSK672 and FGF15 on inhibiting gut bile acid re-uptake and hepatic bile acid synthesis achieve greater magnitude of bile acid pool reduction that not only decreases bile acid burden in NASH livers but also limits intestinal lipid absorption, which, together with FGF15 signaling activation, produces weight loss, reduction of adipose inflammation, and attenuated hepatocellular organelle stress. Bile Acids and Salts 79-88 fibroblast growth factor 15 Mus musculus 55-60 33965587-7 2021 Mechanistically, the synergistic actions of GSK672 and FGF15 on inhibiting gut bile acid re-uptake and hepatic bile acid synthesis achieve greater magnitude of bile acid pool reduction that not only decreases bile acid burden in NASH livers but also limits intestinal lipid absorption, which, together with FGF15 signaling activation, produces weight loss, reduction of adipose inflammation, and attenuated hepatocellular organelle stress. Bile Acids and Salts 111-120 fibroblast growth factor 15 Mus musculus 55-60 33965587-7 2021 Mechanistically, the synergistic actions of GSK672 and FGF15 on inhibiting gut bile acid re-uptake and hepatic bile acid synthesis achieve greater magnitude of bile acid pool reduction that not only decreases bile acid burden in NASH livers but also limits intestinal lipid absorption, which, together with FGF15 signaling activation, produces weight loss, reduction of adipose inflammation, and attenuated hepatocellular organelle stress. Bile Acids and Salts 111-120 fibroblast growth factor 15 Mus musculus 55-60 33965587-7 2021 Mechanistically, the synergistic actions of GSK672 and FGF15 on inhibiting gut bile acid re-uptake and hepatic bile acid synthesis achieve greater magnitude of bile acid pool reduction that not only decreases bile acid burden in NASH livers but also limits intestinal lipid absorption, which, together with FGF15 signaling activation, produces weight loss, reduction of adipose inflammation, and attenuated hepatocellular organelle stress. Bile Acids and Salts 111-120 fibroblast growth factor 15 Mus musculus 55-60 33965587-8 2021 Furthermore, the combined treatment attenuates increased fecal bile acid excretion and repressed bile acid synthesis, which underlie diarrhea and hypercholesterolemia associated with ASBT inhibition and FGF19 analogue, respectively, in clinical settings. Bile Acids and Salts 97-106 fibroblast growth factor 15 Mus musculus 203-208 32198567-10 2021 DCA-induced dysbiosis decreased the deconjugation of bile acids, and this regulation was associated with the repressed expression of target genes in the enterohepatic farnesoid X receptor-fibroblast growth factor (FXR-FGF15) axis, leading to upregulation of hepatic de novo bile acid synthesis. Bile Acids and Salts 53-63 fibroblast growth factor 15 Mus musculus 218-223 32198567-10 2021 DCA-induced dysbiosis decreased the deconjugation of bile acids, and this regulation was associated with the repressed expression of target genes in the enterohepatic farnesoid X receptor-fibroblast growth factor (FXR-FGF15) axis, leading to upregulation of hepatic de novo bile acid synthesis. Bile Acids and Salts 53-62 fibroblast growth factor 15 Mus musculus 218-223 33484478-2 2021 Monomeric FGF19 and dimeric Fgf15 are both necessary for liver regeneration and proper bile acid (BA) metabolism. Bile Acids and Salts 87-96 fibroblast growth factor 15 Mus musculus 10-15 33484478-2 2021 Monomeric FGF19 and dimeric Fgf15 are both necessary for liver regeneration and proper bile acid (BA) metabolism. Bile Acids and Salts 87-96 fibroblast growth factor 15 Mus musculus 28-33 33484478-2 2021 Monomeric FGF19 and dimeric Fgf15 are both necessary for liver regeneration and proper bile acid (BA) metabolism. Bile Acids and Salts 98-100 fibroblast growth factor 15 Mus musculus 10-15 33484478-2 2021 Monomeric FGF19 and dimeric Fgf15 are both necessary for liver regeneration and proper bile acid (BA) metabolism. Bile Acids and Salts 98-100 fibroblast growth factor 15 Mus musculus 28-33 33127558-10 2021 The composition of GM is significantly changed with an increase in BA-metabolizing bacteria, leading to an increased expression of ileal FGF15 driven by FXR that has a higher affinity to unconjugated BAs. Bile Acids and Salts 67-69 fibroblast growth factor 15 Mus musculus 137-142 35462858-8 2022 Increased expression levels of ileal Fgf15, and decreased Asbt expression in Ostbeta -/- mice indicate the accumulation of bile acids in the enterocyte. Bile Acids and Salts 123-133 fibroblast growth factor 15 Mus musculus 37-42 35133032-0 2022 TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk. Bile Acids and Salts 53-62 fibroblast growth factor 15 Mus musculus 35-40 35133032-1 2022 FGF19/FGF15 is an endocrine regulator of hepatic bile salt and lipid metabolism, which has shown promising effects in the treatment of NASH in clinical trials. Bile Acids and Salts 49-58 fibroblast growth factor 15 Mus musculus 0-5 35133032-1 2022 FGF19/FGF15 is an endocrine regulator of hepatic bile salt and lipid metabolism, which has shown promising effects in the treatment of NASH in clinical trials. Bile Acids and Salts 49-58 fibroblast growth factor 15 Mus musculus 6-11 33631374-9 2021 This was also associated with increased intestinal FXR/Fgf15 signaling, which inhibits hepatic synthesis of bile acids. Bile Acids and Salts 108-118 fibroblast growth factor 15 Mus musculus 55-60 32404932-3 2020 Intestinal FXR is critical in suppressing hepatic bile acid (BA) synthesis by inducing fibroblast growth factor 15 (FGF15) in mice and FGF19 in humans. Bile Acids and Salts 61-63 fibroblast growth factor 15 Mus musculus 87-114 33144503-1 2020 As a physiological regulator of bile acid homeostasis, FGF19 is also a potent insulin sensitizer capable of normalizing plasma glucose concentration, improving lipid profile, ameliorating fatty liver disease, and causing weight loss in both diabetic and diet-induced obesity mice. Bile Acids and Salts 32-41 fibroblast growth factor 15 Mus musculus 55-60 33144503-4 2020 Here, we show that nonmitogenic FGF19 variants that retain the full beneficial glucose-lowering and bile acid regulatory activities of WT FGF19 (FGF19WT) can be engineered by diminishing FGF19"s ability to induce dimerization of its cognate FGF receptors (FGFR). Bile Acids and Salts 100-109 fibroblast growth factor 15 Mus musculus 32-37 33144503-4 2020 Here, we show that nonmitogenic FGF19 variants that retain the full beneficial glucose-lowering and bile acid regulatory activities of WT FGF19 (FGF19WT) can be engineered by diminishing FGF19"s ability to induce dimerization of its cognate FGF receptors (FGFR). Bile Acids and Salts 100-109 fibroblast growth factor 15 Mus musculus 138-143 33144503-4 2020 Here, we show that nonmitogenic FGF19 variants that retain the full beneficial glucose-lowering and bile acid regulatory activities of WT FGF19 (FGF19WT) can be engineered by diminishing FGF19"s ability to induce dimerization of its cognate FGF receptors (FGFR). Bile Acids and Salts 100-109 fibroblast growth factor 15 Mus musculus 145-152 33144503-4 2020 Here, we show that nonmitogenic FGF19 variants that retain the full beneficial glucose-lowering and bile acid regulatory activities of WT FGF19 (FGF19WT) can be engineered by diminishing FGF19"s ability to induce dimerization of its cognate FGF receptors (FGFR). Bile Acids and Salts 100-109 fibroblast growth factor 15 Mus musculus 138-143 33107729-8 2020 Naringin modulated the abundances of bile salt hydrolase- and 7alpha-dehydroxylase-producing bacteria, promoting bile acid synthesis from cholesterol by upregulating CYP7A1 via suppression of the FXR/FGF15 pathway. Bile Acids and Salts 37-46 fibroblast growth factor 15 Mus musculus 200-205 32681035-5 2020 Furthermore, we find that cholesterol-induced lysosomal stress feed-forward activates TFEB via promoting TFEB nuclear translocation, while bile acid-induced fibroblast growth factor 19 (FGF19), acting via mTOR/ERK signaling and TFEB phosphorylation, feedback inhibits TFEB nuclear translocation in hepatocytes. Bile Acids and Salts 139-148 fibroblast growth factor 15 Mus musculus 157-184 32681035-5 2020 Furthermore, we find that cholesterol-induced lysosomal stress feed-forward activates TFEB via promoting TFEB nuclear translocation, while bile acid-induced fibroblast growth factor 19 (FGF19), acting via mTOR/ERK signaling and TFEB phosphorylation, feedback inhibits TFEB nuclear translocation in hepatocytes. Bile Acids and Salts 139-148 fibroblast growth factor 15 Mus musculus 186-191 32681035-6 2020 Consistently, blocking intestinal bile acid uptake by an apical sodium-bile acid transporter (ASBT) inhibitor decreases ileal FGF15, enhances hepatic TFEB nuclear localization and improves cholesterol homeostasis in Western diet-fed mice. Bile Acids and Salts 34-43 fibroblast growth factor 15 Mus musculus 126-131 32967428-3 2020 Fibroblast growth factor 19 (FGF19) in human and its murine orthologue Fgf15 plays a pivotal role in this bile acid driven enterohepatic signaling. Bile Acids and Salts 106-115 fibroblast growth factor 15 Mus musculus 71-76 32967428-11 2020 Intact Fgf15 mediated enterohepatic bile acid signaling, but not changes in bile acid flux, appear to be important for the metabolic improvements post-murine bariatric surgery. Bile Acids and Salts 36-45 fibroblast growth factor 15 Mus musculus 7-12 32639145-7 2020 Importantly, teneligliptin suppressed the expression of the BA synthesis inhibitory factor Fgf15, which was mediated through phosphatidylinositol 3-kinase (PI3K)/AKT/Kruppel-like factor 15 (KLF15) signaling. Bile Acids and Salts 60-62 fibroblast growth factor 15 Mus musculus 91-96 32681035-0 2020 An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis. Bile Acids and Salts 66-75 fibroblast growth factor 15 Mus musculus 3-11 32404932-3 2020 Intestinal FXR is critical in suppressing hepatic bile acid (BA) synthesis by inducing fibroblast growth factor 15 (FGF15) in mice and FGF19 in humans. Bile Acids and Salts 61-63 fibroblast growth factor 15 Mus musculus 116-121 32404932-3 2020 Intestinal FXR is critical in suppressing hepatic bile acid (BA) synthesis by inducing fibroblast growth factor 15 (FGF15) in mice and FGF19 in humans. Bile Acids and Salts 61-63 fibroblast growth factor 15 Mus musculus 135-140